Logo

PharmaShots Weekly Snapshots (August 30 - September 03, 2021)

Share this

PharmaShots Weekly Snapshots (August 30 - September 03, 2021)

Forte's FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis

Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis

Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis

Pfizer Initiates P-III RENOIR Trial of RSVpreF Vaccine for the Treatment of Respiratory Syncytial Virus

Published: Sept 3, 2021 | Tags: Pfizer, P-III, RENOIR trial, RSVpreF Vaccine, Respiratory Syncytial Virus

Alexion's Ultomiris (ravulizumab) Receives EC's Approval for Expanded Use to Treat Paroxysmal Nocturnal Haemoglobinuria

Published: Sept 3, 2021 | Tags: Alexion, Ultomiris, ravulizumab, EC, Approval, Paroxysmal Nocturnal Haemoglobinuria, EU

Abbott to Acquire Walk Vascular to Bolster its Peripheral Vascular Offerings

Published: Sept 3, 2021 | Tags: Abbott, Walk Vascular, Thrombectomy System, Peripheral Blood Clots

Baxter to Acquire Hillrom for ~$10.5B

Published: Sept 3, 2021 | Tags: Baxter, Acquire, Hillrom, ~$10.5B

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

Published: Sept 2, 2021 | Tags: Janssen, Invega Hafyera, paliperidone palmitate, US, FDA, Approval, Schizophrenia

Astellas Pauses Dosing of AT132 in ASPIRO Clinical Trial for the Treatment of X-linked Myotubular Myopathy

Published: Sept 2, 2021 | Tags: Astellas, Dosing, AT132, ASPIRO Clinical Trial, X-linked Myotubular Myopathy

BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Approval for the Treatment of Waldenström's Macroglobulinemia

Published: Sept 2, 2021 | Tags: BeiGene, Brukinsa, Zanubrutinib, US, FDA, Approval, Waldenström's Macroglobulinemia

BMS Exercised Its Option to License Evotec's EVT8683 for the Treatment of Neurodegenerative Disease

Published: Sept 2, 2021 | Tags: BMS, Exercised Its Option, License, Evotec, EVT8683

Takeda's Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer

Published: Sept 2, 2021 | Tags: Takeda, Pevonedistat, Azacitidine, P-III, PANTHER Trial, Cancer

AstraZeneca Signs a Multiyear Agreement with Thermo Fisher to Co-Develop NGS-based CDx for Targeted Therapies

Published: Sept 2, 2021 | Tags: AstraZeneca, Thermo Fisher, Co-Develop, NGS-based CDx, Targeted Therapies

Merck and Ridgeback Initiate P-III MOVe-AHEAD Study of Molnupiravir for the Prevention of COVID-19 Infection

Published: Sept 1, 2021 | Tags: Merck, Ridgeback, P-III, MOVe-AHEAD Study, Molnupiravir, COVID-19

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Label Update to Treat Advanced Urothelial Carcinoma

Published: Sept 1, 2021 | Tags: Merck, Keytruda, Pembrolizumab, US, FDA, Approval, Urothelial Carcinoma

Johnson & Johnson Discontinues the P-IIb Imbokodo Trial of HIV Vaccine Regimen for HIV Infection

Published: Sept 1, 2021 | Tags: Johnson & Johnson, P-IIb, Imbokodo Trial, HIV Vaccine Regimen, HIV Infection

Bayer Initiates P-III OASIS Program of Elinzanetant for the Treatment of Vasomotor Symptoms During Menopause

Published: Sept 1, 2021 | Tags: Bayer, P-III, OASIS Program, Elinzanetant, Vasomotor Symptoms, Menopause

AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease

Published: Sept 1, 2021 | Tags: AC Immune, Semorinemab, P-II, Lauriet Study, Alzheimer's Disease

Novartis Signs an Agreement with NHS to Commercialize Leqvio (inclisiran) for the Treatment of Cardiovascular Disease

Published: Sept 1, 2021 | Tags: Novartis, NHS, Commercialize, Leqvio, inclisiran, Cardiovascular Disease

Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021

Published: Aug 31, 2021 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, P-III, EMPEROR-Preserved Trial, HFpEF ESC 2021

Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary Arterial Hypertension #ESC2021

Published: Aug 31, 2021 | Tags: Janssen, Uptravi, selexipag, P-III, GRIPHON, P-IIIb, TRITON Clinical Trials, Pulmonary Arterial Hypertension

Baxter in Talks to Acquire Hill-Rom for ~$10B

Published: Aug 31, 2021 | Tags: Baxter, Acquire, Hill-Rom, ~$10B

Bone Therapeutics's JTA-004 Fails to Meet its All Endpoints in P-III Study for Knee Osteoarthritis

Published: Aug 31, 2021 | Tags: Bone Therapeutics, JTA-004, P-III, Study, Knee Osteoarthritis

GSK and SK Bioscience Initiate P-III Study of GBP510 Against AZ/Oxford's COVID-19 Vaccine

Published: Aug 31, 2021 | Tags: GSK, SK Bioscience, P-III, Study, GBP510, AZ/Oxford's COVID-19 Vaccine

Abbott Reports Head-to-Head Data for Amplatzer Amulet Against Boston Scientific's Watchman Device to Treat Atrial Fibrillation #ESC2021

Published: Aug 31, 2021 | Tags: Abbott, Amplatzer Amulet, Boston Scientific, Watchman Device, Atrial Fibrillation, ESC2021

Pfizer Reports Results of Abrocitinib in P-III JADE DARE Study to Treat Atopic Dermatitis

Published: Aug 30, 2021 | Tags: Pfizer, Abrocitinib, P-III, JADE DARE Study, Atopic Dermatitis

SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma

Published: Aug 30, 2021 | Tags: SpringWorks, Dana-Farber, Nirogacestat, Multiple Myeloma

Sanofi and Regeneron's Dupixent Meets All Endpoints in P-III Study in Children with Atopic Dermatitis

Published: Aug 30, 2021 | Tags: Sanofi, Regeneron, Dupixent, P-III, Study, Atopic Dermatitis

Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar, ustekinumab) in the US

Published: Aug 30, 2021 | Tags: Bio-Thera, Hikma, Exclusive Commercialization, License Agreement, BAT2206, biosimilar, ustekinumab, US

MicroTransponder Receives the US FDA's Approval for Vivistim System as the First Vagus Nerve Stimulation Implant for Stroke Rehabilitation

Published: Aug 30, 2021 | Tags: MicroTransponder, US, FDA, Approval, Vivistim System, First Vagus Nerve Stimulation Implant, Stroke Rehabilitation

BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors

Published: Aug 30, 2021 | Tags: BeiGene, ImmixBio, IMX-110, Tislelizumab, Solid Tumors

Related Post: PharmaShots Weekly Snapshots (August 23 - 27, 2021)


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions